Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells.
Park SH, Kim JH, Ko E, Kim JY, Park MJ, Kim MJ, Seo H, Li S, Lee JY.
Park SH, et al. Among authors: seo h.
FASEB J. 2018 May 29:fj201800011R. doi: 10.1096/fj.201800011R. Online ahead of print.
FASEB J. 2018.
PMID: 29812969
Our data suggest that disruption of the Keap1-Nrf2 pathway is one of the mechanisms by which EGFR-TKI resistance occurs, a fact that must be considered when treating patients with EGFR-TKI.-Park, S.-H., Kim, J. H., Ko, E., Kim, J.-Y., Park, M.-J., Kim, M. J., Seo …
Our data suggest that disruption of the Keap1-Nrf2 pathway is one of the mechanisms by which EGFR-TKI resistance occurs, a fact that must be …